36E79726Q0005 RFI mod.docx

DOCX document 28 KB Posted

Attached to
Roflumilast Tablets (VA-27-00006601)
Solicitation number
36E79726Q0005
Issued by

About this file

This is a Sources Sought Notice for market research regarding the procurement of Roflumilast Tablets for multiple federal agencies. The Department of Veterans Affairs National Acquisition Center is conducting market research for the Department of Veterans Affairs (VA), Department of Defense (DoD), Indian Health Service (IHS), Bureau of Prisons (BOP), and Federal Health Care Center (FHCC). This procurement will result in a national mandatory requirements contract with other companies offering the same or similar products blocked from ordering. The anticipated contract structure includes a base year plus up to four option years to ensure long-term continuity and committed volume purchases at prices lower than Federal Supply Schedule or open market rates.

Respondents must meet specific minimum requirements including: possessing a unique eleven-digit National Drug Code (NDC) with the first five digits identifying the offeror; providing a manufacturer's letter of commitment if not the manufacturer; maintaining business-to-business agreements with the Pharmaceutical Prime Vendor Program; confirming business size classification under NAICS code 325412; and confirming U.S. manufacturing or Trade Agreements Act compliance. The procurement covers three line items: Roflumilast 250 MCG tablets (28-count bottles, 11,870 annual units); Roflumilast 500 MCG tablets (30-count bottles, 18,916 annual units); and Roflumilast 500 MCG tablets (90-count bottles, 13,880 annual units). All products must meet specific unit-of-use packaging requirements including childproof closures, minimum 120cc bottle volume, cylindrical shape with 5.75-inch minimum circumference, and label dimensions of 5.25" x 2". Respondents must confirm ability to begin supply within 60 days of contract award. The response deadline is September 17, 2026, at 2:30 PM Central Time, with responses directed to Contract Specialist Kenneth Lay at Kenneth.Lay@va.gov.

View the file

On GovTribe

Work with this file

  • Download the original file
  • Contacts named in this file
  • Similar government files
  • Ask GovTribe AI about this file

Text version

Sources Sought Notice Sources Sought Notice

SUBJECT*
Roflumilast Tablets (VA-27-00006601)

GENERAL INFORMATION

CONTRACTING OFFICE’S ZIP CODE*
60141
SOLICITATION NUMBER*
36E79726Q0005
RESPONSE DATE/TIME/ZONE
09-17-2026 2:30PM CENTRAL TIME, CHICAGO, USA
ARCHIVE
30 DAYS AFTER THE RESPONSE DATE
RECOVERY ACT FUNDS
N

SET-ASIDE

PRODUCT SERVICE CODE*
6505
NAICS CODE*
325412

CONTRACTING OFFICE ADDRESS

POINT OF CONTACT*

Contract Specialist Kenneth Lay Kenneth.Lay@va.gov

PLACE OF PERFORMANCE

ADDRESS

POSTAL CODE

COUNTRY

ADDITIONAL INFORMATION

AGENCY’S URL

URL DESCRIPTION

AGENCY CONTACT’S EMAIL ADDRESS

EMAIL DESCRIPTION

DESCRIPTION

I am conducting market research for the procurement of Roflumilast Tablets, for the Department of Veterans Affairs (VA), Department of Defense (DoD), Indian Health Service (IHS), Bureau of Prisons (BOP), and Federal Health Care Center (FHCC). This procurement will result in national mandatory requirements contract for the above agencies. Other companies with the same/similar product will be blocked out for ordering; therefore it is our goal to award lower than FSS/Open Market prices on the resultant national contract based on purchases of a committed volume. These products will be awarded in the aggregate for all strengths and sizes for the base year and all option years included in the solicitation. Please provide a response to the following:

1. Is your Company able to meet the following minimum requirements:

a. National Drug Code (NDC): Offerors shall provide a separate and distinct eleven-digit NDC number unique to the offeror (e.g., 00012-3456-78) for each product proposed. The first five numbers of the eleven-digit NDC number for each product proposed shall identify the offeror. Additionally, the successful offeror/contractor’s label with its unique NDC shall be the only label on the product. Contractors shall not affix their label over another label on the product. Does your company have a unique NDC (Labeler Code)?_____________

b. If the offeror is not the manufacturer of the offered items, the offeror shall submit a letter of commitment from the manufacturer to the offeror which will assure the offeror a source of supply sufficient to satisfy the Government's requirements for the contract period. Name of Manufacturer: _________________

Would you be able to provide a letter of commitment from the manufacturer of the offered drug? _____________

c. Pharmaceutical Prime Vendor: All Ordering Activities under the Department of Veterans Affairs and Department of Defense acquire their pharmaceutical requirements through their Pharmaceutical Prime Vendor Program (PPV). The contractor shall ensure that chargeback agreements with the PPVs have been executed with sufficient time to permit the PPVs to begin timely distribution of Government orders, if an award is made. Does your company currently have a business-to-business agreement with the PPVs?_________

d. Under NAICS code 325412, is your company size (check one):

Large Business ______ Small Business ______

e. If a small business, does your company manufacture (measure, weigh, mix, and compound) at least 50% of the product offered?_________

f. Is the offered end product U.S-made or an end product of a Trade Agreements Act designated country?_________

g. Can your company meet the following product, bottle size and usage? Please indicate any details or comments.

Item
Description
Package Size (Tablets per Bottle)
Total Estimated Annual Usage (Bottles)
1
ROFLUMILAST 250MCG TAB
28
11,870
2
ROFLUMILAST 500MCG TAB
30
18,916
3
ROFLUMILAST 500MCG TAB
90
13,880

2. Is your Company interested in submitting a response to a solicitation?________

3. As this is a national standardized contract, our preference is for a base plus four option years to provide our customers with continuity and consistency of product by allowing for long-term committed purchases of your product. If interested, please indicate Base year and how many Option periods, not to exceed 4._________________

4. If an award were to be made based on the above requirements, would your company be able to begin supplying the product in the estimated quantities within 60 days of the contract award date?

5. If your company is not interested in participating, please respond with the reason why. This aids our market research for future procurements.

6. VA intends to require in the solicitation that proposed products are in unit of use package sizes for all line items (28/30/90-count bottles). VA defines unit of use package sizes as follows: Unit of use package sizes must contain a child proof closure (safety cap) and a bottle with a minimum required size of 120cc volume. The safety cap must not exceed the diameter of the bottle. The bottle must have a cylindrical body and minimum of 5.75” circumference. The bottle must fit a label with a dimension of 5.25” x 2”. The 0.5” additional space is required to keep the bar code exposed and/or allow for the display of the expiration date and lot number. Please indicate if your company can provide the products above meeting these packaging requirements.

*Note that we will accept the 250MCG product in blister packs or bottles. If the 250MCG is offered in bottles, it must meet the unit of use bottle requirements. The 500MCG products must meet unit of use bottle requirements.

If you could provide your responses by next Friday, September 17, 2026, it would be greatly appreciated. Please contact me at Kenneth.Lay@va.gov if you have any questions.

*= Required Field
Sources Sought Notice

Sources Sought Notice

File details come from the government source that posted it. Updated .